Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $37 | $99 | $55 | $259 |
| - Cash | $8,083,085 | $15 | $23 | $17 |
| + Debt | $247,698 | $30 | $36 | $11 |
| Enterprise Value | -$7,835,350 | $114 | $67 | $252 |
| Revenue | $1,413,535 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $57,205 | -$0 | -$0 | -$0 |
| % Margin | 4% | – | – | – |
| EBITDA | -$67,061,666 | -$72 | -$57 | -$64 |
| % Margin | -4,744.3% | – | – | – |
| Net Income | -$62,424,863 | -$75 | -$59 | -$66 |
| % Margin | -4,416.2% | – | – | – |
| EPS Diluted | -1.79 | -4.06 | -4.72 | -6.23 |
| % Growth | 55.9% | 14% | 24.2% | – |
| Operating Cash Flow | -$51,829,437 | -$69 | -$43 | -$57 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$51,829,437 | -$69 | -$43 | -$57 |